FNIH Biomarkers Consortium and Critical Path Institute achieve qualification of a clinical safety biomarker
On Oct. 25, 2018, The Foundation for the National Institutes of Health, Biomarkers Consortium and the Critical Path Institute Predictive Safety Testing Consortium (PSTC) announced they had received the first ever qualification of a clinical safety biomarker awarded by the U.S. Food and Drug Administration (FDA) – a major milestone that will improve the detection of drug-induced kidney injury in early phase drug development.
Tags:
Source: Foundation for the National Institutes of Health
Credit: